Zachary Reitman

Affiliations: 
Dana-Farber Cancer Institute, Boston, MA, United States 
Google:
"Zachary Reitman"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Waitkus MS, Erman EN, Reitman ZJ, et al. (2024) Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas. Neuro-Oncology
Low JT, Brown MC, Reitman ZJ, et al. (2024) Understanding and therapeutically exploiting cGAS/STING signaling in glioblastoma. The Journal of Clinical Investigation. 134
Koschmann C, Al-Holou WN, Alonso MM, et al. (2023) A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell
Tu KJ, Diplas BH, Regal JA, et al. (2023) Mining cancer genomes for change-of-metabolic-function mutations. Communications Biology. 6: 1143
Mangoli A, Wu S, Liu HQ, et al. (2023) ( ) disruption sensitizes spatially-directed H3.3K27M/TP53 diffuse midline gliomas to radiation therapy. Biorxiv : the Preprint Server For Biology
Jones JK, Zhang H, Lyne AM, et al. (2023) ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination. Neuro-Oncology Advances. 5: vdad095
Tu KJ, Stewart CE, Hendrickson PG, et al. (2023) Pooled genetic screens to identify vulnerabilities in TERT-promoter-mutant glioblastoma. Oncogene
Regal JA, Guerra García ME, Jain V, et al. (2023) Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population. Acta Neuropathologica Communications. 11: 50
Stewart CE, Guerra-García ME, Luo L, et al. (2022) The Effect of Loss on Radiosensitivity of a Primary Mouse Model of -Deleted Brainstem Glioma. Cancers. 14
Khadka P, Reitman ZJ, Lu S, et al. (2022) PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nature Communications. 13: 604
See more...